ALK-Abelló
154.8
DKK
-1.21 %
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
15 following
-1.21%
-3.07%
-10.26%
-4.09%
+1.84%
+52.96%
+63.81%
-3.01%
+91.23%
+348.7%
ir.alk.net
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.
Revenue
4.82B
EBIT %
13.81 %
P/E
70.36
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
ALK B
Daily low / high price
154 / 155.8
DKK
Market cap
34.49B DKK
Turnover
3.77M DKK
Volume
24K
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| The Lundbeck Foundation | 40.3 % | 67.2 % |
| The Danish Labour Market Supplementary Pension ( ATP) | 7.5 % | 4.1 % |
| ALK - own shares | 1.9 % | 1.9 % |
ShowingAll content types
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools